Medical device and MedTech insights, news, tips and more

AccurKardia’s AccurECG™ Analysis System Receives FDA 510(k) Clearance

July 12, 2023


AccurKardia, a medical technology company delivering clinical-grade ECG interpretation software, announced today that its flagship product, the AccurECG™ Analysis System (“AccurECG” or the “System”), has been granted FDA 510(k) clearance. AccurECG™ is a cloud-based, device-agnostic and fully automated electrocardiogram (ECG) interpretation software platform.

The groundbreaking AccurECG™ software provides an array of benefits, such as beat-by-beat analysis, ventricular/supraventricular ectopic beat detection, heart rate measurement and automated interpretation of 13 different heart rhythms including sinus tachycardia, sinus bradycardia, atrial fibrillation and atrial flutter, among others. It provides Lead II analysis of data obtained from compatible ECG devices with wet electrodes such as holter monitors, event recorder and/or cardiac telemetry devices. The fully automated output of AccurECG™ improves clinicians’ review efficiencies and enables prompt treatment of patients, with results delivered in minutes. It is indicated for adults aged 22 and older.

Juan C. Jiménez, CEO of AccurKardia, remarked, “Receiving FDA 510(k) clearance is a significant milestone for us and we are extremely proud of what we have built. AccurECG™ is set to revolutionize remote cardiac care, making it more accessible and efficient across the Nation. By providing a device-agnostic, medical-grade solution with explainable output and no ‘black box’ approach, we aim to empower healthcare providers with accurate, fast, efficient and transparent ECG interpretation.”

The System’s key benefits range from customizable outputs and configurations to seamless integration with established clinical workflows in an HIPAA compliant manner. Its cloud-based SaaS model assists cardiac monitoring companies by delivering a solution that can improve their service and response time for analysis.

AccurKardia’s offering helps improve clinical outcomes delivering a prompt analysis while minimizing false positives compared to traditional computational interpretation offerings1 available in the market. Based on clinical data reported to FDA in a third-party clinical retrospective study, AccurECG™ has demonstrated an average aggregate sensitivity and specificity of approximately 96% and 99%, respectively, in detecting arrhythmias across its covered 13 heart rhythms.

Dr. Nav Razvi, Chief Medical Officer of AccurKardia, said, “Our team at AccurKardia is incredibly proud to achieve FDA 510(k) clearance for the AccurECG™ Analysis System. This clearance signifies a great stride forward in advancing remote cardiac care. The AccurECG solution can enable specialist-level ECG interpretation in communities and services that do not have ready access, as well as increasing the efficiency of workflow for busy clinical practitioners.”

About AccurKardia

AccurKardia delivers automated clinical-grade ECG interpretation software to cardiac monitoring companies, thereby expanding access to the benefits of remote cardiac care to millions of patients worldwide. AccurKardia combines proprietary AI and non-AI based techniques to provide near-real-time ECG analytics in the cloud, on device, and at the edge. For more information about AccurKardia, please visit:

See Full Press Release at the Source: AccurKardia’s AccurECG™ Analysis System Receives FDA 510(k) Clearance

Press Release by: AccurKardia

Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 18 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.